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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and medically refractory lung disease with a grim
prognosis. Although the etiology of IPF remains perplexing, abnormal adaptive immune responses are evident in many
afflicted patients. We hypothesized that perturbations of human leukocyte antigen (HLA) allele frequencies, which are often
seen among patients with immunologic diseases, may also be present in IPF patients.
Methods/Principal Findings: HLA alleles were determined in subpopulations of IPF and normal subjects using molecular
typing methods. HLA-DRB1*15 was over-represented in a discovery cohort of 79 Caucasian IPF subjects who had lung
transplantations at the University of Pittsburgh (36.7%) compared to normal reference populations. These findings were
prospectively replicated in a validation cohort of 196 additional IPF subjects from four other U.S. medical centers that
included both ambulatory patients and lung transplantation recipients. High-resolution typing was used to further define
specific HLA-DRB1*15 alleles. DRB1*1501 prevalence in IPF subjects was similar among the 143 ambulatory patients and 132
transplant recipients (31.5% and 34.8%, respectively, p = 0.55). The aggregate prevalence of DRB1*1501 in IPF patients was
significantly greater than among 285 healthy controls (33.1% vs. 20.0%, respectively, OR 2.0; 95%CI 1.3–2.9, p = 0.0004). IPF
patients with DRB1*1501 (n = 91) tended to have decreased diffusing capacities for carbon monoxide (DLCO) compared to
the 184 disease subjects who lacked this allele (37.861.7% vs. 42.861.4%, p = 0.036).
Conclusions/Significance: DRB1*1501 is more prevalent among IPF patients than normal subjects, and may be associated
with greater impairment of gas exchange. These data are novel evidence that immunogenetic processes can play a role in
the susceptibility to and/or manifestations of IPF. Findings here of a disease association at the HLA-DR locus have broad
pathogenic implications, illustrate a specific chromosomal area for incremental, targeted genomic study, and may identify a
distinct clinical phenotype among patients with this enigmatic, morbid lung disease.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, morbid,
fibroproliferative lung disease that manifests with progressive
pulmonary restriction and gas exchange abnormalities [1]. The
age- and gender-adjusted prevalence of this disease in the U.S. has
been recently estimated as 28 to 63 cases per 100,000 persons, and
may be increasing [2]. IPF has a dismal prognosis, with a median
survival of approximately 3 years after diagnosis, and no medical
treatments have proven efficacy [1,3].
Despite extensive investigation, the etiology of IPF remains
obscure. Although the pulmonary fibrosis that characterizes this
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disease is often considered to be uniquely dissociated from
inflammatory processes [3], studies of patient-derived specimens
show that abnormal adaptive immune responses are common in
IPF [4–18].
HLA allele frequencies are often aberrantly distributed among
patients with immunologic disorders [19–24]. However, HLA
characterizations of IPF populations have not been extensively
pursued, particularly among disease cohorts that have been
delineated by contemporaneous diagnostic criteria [1] and use of
definitive, molecular allele typing.
We hypothesized that HLA frequency perturbations may also
occur in IPF. Given the apparent prominence of CD4 T-cell
responses in IPF [4–9,14–17], we were singularly interested in
evaluating the HLA Class II allele frequencies of these patients,
since CD4 lymphocytes are predominantly HLA Class II-
dependent [25]. Findings of HLA allele biases in IPF could have
significant implications for the role of immunogenetic mechanisms
in the pathogenesis of this disease.
Methods
Subjects
The initial (discovery) IPF cohort consisted of 79 consecutive
patients with end-stage pulmonary disease who had molecular
HLA allele determinations during evaluations for lung transplan-
tations at the University of Pittsburgh (U. Pgh.), beginning in
March 2006.
The subsequent disease validation cohorts were composed of
IPF subjects for whom molecular HLA typing results and/or tissue
specimens for HLA typing were available from the National
Institute of Health (NIH) (n = 35), University of Chicago Medical
Center (n = 32), Inova Fairfax Hospital (n = 20), and Stanford
University Medical Center (n = 14). Subjects from Inova and
Stanford were recipients of lung transplantations for end-stage IPF
at their respective medical centers. IPF subjects from the NIH and
University of Chicago were ambulatory clinic patients. In addition,
data were compiled for 19 subjects who had lung transplantations
for end-stage IPF at the U. Pgh. subsequent to the initial
(discovery) analysis (now current thru October 17, 2010), and 76
ambulatory U. Pgh. IPF Clinic patients.
Diagnoses were prospectively established in the IPF subjects by
expert, specialized pulmonary clinicians, blinded to these exper-
imental studies, who analyzed all clinical information, including
medical histories and physical exams, pulmonary function tests
(PFTs), laboratory studies that included serologic tests for
conventional autoimmune syndromes, rheumatologist evaluations,
chest radiographs, and computerized tomography (CT) scans that
were interpreted by radiologists blinded to other study results. All
IPF study subjects fulfilled consensus diagnostic criteria [1]. None
had clinical evidence or a past history of connective tissue diseases,
drug toxicities, or occupational/environmental exposures associ-
ated with interstitial lung disease. Extensive histological evalua-
tions of the diseased pulmonary explants were performed in all
cases by blinded, expert lung pathologists. Subjects were excluded
if they had histological patterns in their explanted lungs other than
usual interstitial pneumonia (UIP) or end-stage fibrotic lung
disease [26].
Right-heart catheterizations were routinely performed during
assessments for lung transplantations (i.e., among U. Pgh., Inova,
and Stanford IPF subjects) by cardiologists who were blinded to
these HLA characterizations or knowledge of this study.
Controls consisted of normal Caucasian subjects who had prior
molecular HLA typing in the course of other investigations at the
U. Pgh. (n = 196) [27] and NIH (n= 41) [28], as well as an
additional, prospectively recruited and analyzed U. Pgh. cohort
(n = 48). All control subjects were healthy, ambulatory volunteers
recruited for study by advertisement and/or solicitation.
Analyses are restricted to Caucasian subjects because ,5% of
lung transplantation recipients in the discovery cohort were
members of minority groups, and HLA allele frequencies can vary
greatly among racial/ethnic subpopulations [29,30].
Subjects gave written informed consent for these studies that
were approved by the respective Institutional Review Boards of all
the participating medical centers (e.g., U. Pgh., NIH, U. Chicago,
Inova, and Stanford).
HLA Typing
HLA characterizations of the initial U. Pgh. IPF and normal
cohorts were performed using DNA isolated from leukocytes, in
sequence specific oligonucleotide probe assays [27]. HLA alleles
among the NIH subjects (both IPF and normal) and the
prospective U. Pgh. normal cohort (n = 48) were evaluated by
polymerase chain reaction using sequence specific primers (PCR-
SSP) (Invitrogen). The presence or absence of DRB1*15 was
determined by PCR-SSP among validation IPF subjects at
Chicago, Inova, Stanford, and the ambulatory U. Pgh IPF
patients. HLA-DRB1* loci typing among those replication cohort
specimens that were positive for DRB1*15, as well as high
resolution typing of HLA-DRB1*15 per se were similarly
performed by PCR-SSP. Previous study of common specimens
confirmed complete concordance of PCR-SSP and oligonucleotide
probe assays (n = 40).
Statistical Methods
Allele-disease associations, as well as comparisons of other
dichotomous variables, were established by Chi square. Logistic
regression analyses were used to generate odds ratios and 95%
confidence intervals. Two-group comparisons of continuous
variables were made by two-sample t-test. Factorial ANOVA
was used for three or more group comparisons of demographic
and physiologic data, with post-hoc comparisons by Bonferroni/
Dunn. Analyses were conducted with StatView v5.0.1 (SAS
Institute, Cary, NC). Alpha (p) values ,0.05 were considered
significant. Data are depicted as means6SE.
Results
IPF Subjects
A total of 275 IPF subjects were studied here (Table 1). The IPF
lung transplantation recipients from the U. Pgh., Inova, and
Stanford had comparable pulmonary function abnormalities,
although U. Pgh. and Chicago subjects tended to be older
(Table 1). The extent of pulmonary restriction, ascertained by
forced vital capacities as a percentage of predicted values
(FVC%p), was less severe among ambulatory IPF subjects,
compared to the transplant recipients (6662% vs. 5361%,
respectively, p,0.0001). Similarly, the percentages of predicted
values for single-breath carbon monoxide diffusing capacities
(DLCO%p), an indicator of intrapulmonary gas exchange, were
significantly greater in the ambulatory IPF patients (4862%) than
among those patients who had lung transplantations (3361%)
(p,0.0001).
HLA-DRB1*15 Prevalences
The initial compilation of HLA alleles for the discovery cohort
of 79 U. Pgh. transplantation recipients showed the prevalence of
DRB1*15 (calculated as the proportion of subjects who have either
one or two copies of this allele) was greater among the IPF patients
HLA DRB1*1501 in IPF
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than in a normal control population [27] (Table 2). None of the
other HLA Class II polymorphisms appeared to be significantly
over-represented in these IPF patients (Table 2).
Based on these initial findings, validation cohorts were
prospectively compiled, consisting of HLA data from IPF subjects
at the NIH and results of DRB1*15 determinations using blood or
tissue specimens from IPF patients at U. Chicago, Inova, Stanford,
the IPF outpatient clinic at U. Pgh., as well as an additional
volunteer U. Pgh. healthy control cohort. Those IPF and control
specimens positive for DRB1*15 were further analyzed to
characterize the specific alleles at this locus.
DRB1*15 was present in 64 normal subjects (23%), and in 95
IPF patients (35%) (p= 0.0015). The DRB1*1501 allele accounts
for most DRB1*15 expression in normal Caucasians [29], and
similar findings were present in the subjects here. DRB1*1501
accounted for all but 7 of the DRB1*15 occurrences among the
controls and 4 of the IPF patients, and these exceptions were
instead attributable to DRB1*1502.
The prevalence of DRB1*1501 within the aggregate IPF
replication cohort (32.1%) was comparable to that of the original,
discovery subjects (35.4%) (p = 0.60). Likewise, there was no
significant difference of DRB1*1501 prevalence between IPF
ambulatory patients (31.5%) and IPF transplant recipients (34.8%)
(p = 0.55). The relative distributions of DRB1*1501 genotype
frequencies among the respective control and IPF subpopulations
were also similar in both discovery and replication cohorts
(Table 3). However, the overall prevalence of this allele among
IPF patients was significantly greater than that of the normal
controls (Figure 1).
Five IPF patients were known to have first-degree relatives who
died with lung disease(s) that could possibly have been IPF. Two of
these patients had DRB1*1501. Inasmuch as was known, the
remaining IPF cases were due to sporadic disease [1].
Four (4) pulmonary transplantation recipients with pre-opera-
tive diagnoses of IPF were excluded from analyses on the basis of
lung explant histological evaluation that instead showed single
cases each of: pulmonary vasculitic changes suggestive of a
clinically unsuspected autoimmune disorder; predominant lym-
phangitic non-necrotizing granulomas and lymphocytic infiltrates
more consistent with hypersensitivity pneumonitis or sarcoidosis;
extensive necrotizing granulmatous bronchitis that was highly
suggestive of an infectious etiology; and a clinically unsuspected,
histoplasma pneumonitis. One of these excluded subjects (25%)
had DRB1*1501.
Table 1. IPF Subject Characteristics.
U. Pgh. Tx. NIH U. Chicago Inova Stanford U. Pgh. Amb Aggregate
n 98 35 32 20 14 76 275
Age (years)* 6761 6361 6961 5861 5962 7061 6661
Males (%) 73 69 90 65 57 74 73
Smoking hx (%) 66 69 78 55 57 61 65
Status Tx Amb Amb Tx Tx Amb Both
FVC%p** 5262 74.064 6562 5564 5565 6362 6061
DLCO%p*** 3261 5463 4363 3664 3564 4862 4161
DRB1*15+ (%) 36 (37) 12 (34) 10 (31) 9 (45) 4 (29) 24 (32) 95 (35)
DRB1*1501+ (%) 35 (36) 11 (31) 10 (31) 8 (40) 3 (21) 24 (32) 91 (33)
Tx: transplant recipients; Amb: ambulatory clinic outpatients; hx: history. U.Pgh. Tx includes the 79 subjects of the initial discovery cohort, as well as an additional 19
recipients of lung transplantations for end-stage IPF that have occurred at that institution since the initial discovery compilation. FVC%p denotes forced vital capacity, as
a percentage of predicted normal values; DLCO%p denotes diffusing capacity for carbon monoxide as a percentage of predicted normal values. Values among U. Pgh.
Tx, Inova, and Stanford subjects are based on last determinations immediately prior to their lung transplantations.
*,0.003 for U. Pgh. (both Tx. and OP) and/or U. Chicago vs. all others;
**,0.003 for NIH vs. all other groups; U. Pgh. Tx vs. all Amb subpopulations.
***p,0.004 for NIH vs. all Tx cohorts, U. Pgh. Tx vs. all Amb groups.
doi:10.1371/journal.pone.0014715.t001
Table 2. HLA Class II Allele Prevalence in the Initial IPF
Cohort.
DQB1* Alleles IPF Prevalence
Control
Prevalence p value
02 29.1 40.6 0.07
03 54.4 55.7 0.70
04 3.8 7.8 0.23
05 29.1 31.8 0.67
06 51.9 40.1 0.08
DRB1* Alleles
01 17.7 21.4 0.49
03 20.3 21.4 0.83
04 29.1 28.1 0.86
07 21.5 26.5 0.39
08 3.8 8.7 0.16
09 1.3 1.0 0.86
10 2.5 1.0 0.34
11 16.5 20.9 0.40
12 2.5 3.1 0.81
13 24.1 25.5 0.80
14 5.1 3.6 0.57
15 36.7* 23.0 0.02
16 3.8 5.1 0.64
HLA allele prevalences (the percentages of subjects with one or more copies of
the allele) in the initial U. Pgh. IPF transplant recipient population (n = 79) were
compared to those of a normal reference population (n = 196). DRB1*15 was
the most over-represented of the common HLA Class II alleles among the IPF
(bold) relative to the controls. These initial findings prompted further study by
recruitments of IPF validation cohorts from four other medical centers and high
resolution typing of the DRB1*15 allele (see text).
doi:10.1371/journal.pone.0014715.t002
HLA DRB1*1501 in IPF
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DRB1*1501 Associations with Clinical Parameters
There were no apparent associations between the presence
(n = 91) or absence (n = 184) of DRB1*1501 among the IPF
patients and either age (6661 vs. 6761 years) or gender (75% vs.
73% males), for the DRB1*1501+ and DRB1*1501null subjects,
respectively. Similarly, FVC%p did not consistently differ between
the IPF patients with and without DRB1*1501 (Figure 2A).
However, DLCO%p values were consistently decreased among
the DRB1*1501+ IPF subjects at each study site (Figure 2B). The
mean comparative decrement of this clinically relevant physiologic
parameter (31,32) was ,12% among the DRB1*1501+, compared
to IPF subjects who did not have this allele. This intergroup
difference seemed unlikely to be a cryptic result of smoking per se,
as near equal proportions of IPF subjects with and without
DRB1*1501 had smoking histories (67% and 64%, respectively)
and cumulative smoke exposures (2363 and 2162 pack-years,
respectively). DLCO abnormalities can also be attributable to
secondary effects of pulmonary artery hemodynamics [33].
Nonetheless, we found no intergroup differences of pulmonary
artery pressures based on the presence or absence of DRB1*1501
among those IPF patients who had right heart catheterizations
(i.e., the transplantation recipients from the U. Pgh., Inova, and
Stanford), with respect to systolic (4162 vs. 4362 mm Hg,
respectively), diastolic (1461 vs. 1561 mm Hg, respectively) or
mean pressures (2561 vs. 2661 mm Hg, respectively).
Discussion
These findings show the HLA Class II allele DRB1*1501 is
over-represented among Caucasian IPF subjects with highly
variable disease severities at multiple U.S. medical centers
(Figure 1). The presence of DRB1*1501 in IPF patients also
seems associated with greater magnitudes of gas exchange
impairment (Figure 2B). The present findings implicate immuno-
regulatory elements within the HLA Class II complex in the
pathogenesis of IPF. These data are also consistent with the
hypothesis that the development of IPF likely involves interactions
between environmental agent(s) and genetic factors [34,35], a
disease paradigm also common to many other disorders, notably
including those caused by aberrant immune processes [19–24].
Two distinct mechanisms may account for the frequently
observed associations between unique HLA polymorphisms and
various disease syndromes [19–24]. First, HLA molecules are
requisite effectors for presentations of peptide antigens to the T-
cells that initiate adaptive immune responses, but each distinct
HLA allele has a restricted peptide binding motif [25]. Hence,
HLA haplotype inheritance determines the finite repertoire of
antigens that can evoke T-cell responses in an individual. Although
critical for host defense, these adaptive immune responses may be
deleterious if, as an example, the antigen is a self-protein
(autoantigen), or one that evokes a cross-response to a self-protein
[25,36,37]. In contrast, individuals lacking these specific, ‘‘per-
missive’’ HLA alleles do not present those particular antigens, and
do not initiate the deleterious response(s).
Alternatively, over-representation of a specific HLA molecule(s)
in a disease cohort may be essentially unrelated to the unique
antigen presentations of that HLA per se, but is instead a genetic
‘‘marker’’ denoting the presence of a pathogenic immunomodu-
latory gene(s) that is(are) in strong linkage disequilibrium (LD) with
that HLA allele [21,38].
The human major histocompatibility (MHC) complex on
chromosome 6p21.31 is characterized by the presence of numerous,
extraordinarily polymorphic HLA alleles, and many other proxi-
Figure 1. DRB1*1501 prevalence in IPF and controls. DRB1*1501
was significantly over-represented in the cumulative IPF population
(n = 275) compared to healthy controls (n = 285).
doi:10.1371/journal.pone.0014715.g001
Table 3. Genotype distribution of DRB1*1501.
Cohort Discovery Replication
Subjects Control (n = 196) IPF (n =79) Control (n = 89) IPF (n =196)
Genotype:
DRB1*1501/DRB1*1501 1 (0.5%) 3 (3.8%) 1 (1.1%) 3 (1.5%)
DRB1*1501/other 38 (19.4%) 25 (31.6%) 17 (19.1%) 60 (30.6%)
other/other 157 (80.1%) 51 (64.6%) 71 (79.8%) 133 (67.9%)
p value* 0.0079 0.12
Allele prevalence (any DRB1*1501 present) p value 0.003 0.035
Parentheses denote percentages within respective control and IPF subject cohorts. *denotes p values for the 362 chi-square comparisons of the three genotype
distributions among controls vs. IPF within the discovery or replication cohorts, respectively. The p value of the cumulative 362 chi-square comparison (the three
genotype group distributions among all controls vs. all IPF subjects) is 0.0015.
doi:10.1371/journal.pone.0014715.t003
HLA DRB1*1501 in IPF
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mate immunoregulatory genes that are often in very strong LD [19–
21,26,38]. DRB1*1501 is in nearly complete LD with DQA1*0102
and DQB1*0602 among Caucasians, and is the single most frequent
HLA Class II haplotype in this racial group [29]. Over-
representation of the DRB1*1501 HLA allele (and/or the
DRB1*1501-DQA1*0102-DQB1*0602 haplotype) is also one of
the most frequently reported genetic findings of patients with diverse
immunologic diseases, including Goodpasture’s syndrome, multiple
sclerosis, systemic lupus erythematosus (SLE), and sarcoidosis [19–
24]. Because of the very strong LD within this haplotype, it is
difficult to precisely identify the particular disease-associated HLA
allele among them, or distinguish the contributions of these HLA
from other interspersed immunoregulatory elements, in lieu of
focused, high-resolution genomic studies [21,38,39].
Almost all previous HLA characterizations of IPF patients date
from before the development of precise and definitive molecular
methodologies that distinguish these alleles [40–45] (Table 4).
Moreover, only two of these early serologic-based determinations
examined even a very restricted repertoire of the many, since-
discovered, Class II alleles [44,45]. Furthermore, diagnostic
criteria for IPF have evolved considerably during the intervening
years [1], raising potential concerns about the case definitions of
the earlier study populations. The numbers of subjects among
those investigations were also usually quite small (Table 4),
severely limiting their power to detect intergroup differences.
Despite these potential limitations, however, several of those
earlier investigations indicated HLA allele frequency perturbations
may be present in IPF [40,43–45], although this finding was not
invariable [41,42]. In particular, one of these earlier studies
indicated that DR2, a serologic correlate of HLA-DRB1*15 and,
generally much less frequently, HLA-DRB1*16 gene products,
appeared to be over-represented in IPF subjects (45), a finding
which may be congruent with the current results.
To our knowledge, contemporary analogous analyses using
molecular techniques and current IPF case definitions are limited
to a single cohort study of Mexican patients that reported various
HLA alleles, including DRB1*01, DRB1*04, and DRB1*14, were
over-represented in IPF [46]. We did not see abnormal
frequencies of those particular DRB1* alleles (DRB1*01, *04, or
*14) in our IPF population (Table 2). Conversely, the frequencies
of DRB1*15 alleles in both the IPF and normal control
populations of that previous study [46] were several-fold less than
that measured here, and were also much less than frequencies
reported within other large Caucasian control populations
[22,24,29,30]. The seeming discrepancy between that previous
report and the present findings may be attributable to the often
considerable variability of HLA allele frequencies among different
races and ethnicities [19–21,29].
The present study has several unique aspects. To our
knowledge, the number of subjects with this uncommon disease
that were analyzed here is unprecedented among analogous
investigations (Table 4). The findings of DRB1*15 over-represen-
tation in the discovery U. Pgh. cohort with end-stage lung disease
was also uniquely validated in prospective replications of subjects
from four other participating medical centers, and included IPF
patients with highly variable disease severities. The present study is
also unusual in that, in addition to adherence with current
diagnostic criteria [1], extensive histological evaluations of entire
lung explants were available for the many disease subjects here
who had lung transplantations, thereby further ensuring accuracy
of these case definitions.
Other findings here that DLCO tended to be comparatively less
among those IPF patients with DRB1*1501 (Figure 2B), partic-
ularly in the absence of confounding by intergroup differences of
smoking exposures or pulmonary artery pressures, could perhaps
imply that the role ultimately played by this immunogenetic
factor(s) may have a singularly virulent effect with respect to the
lung injury mechanisms that result in gas exchange impairment.
Decrements of DLCO are widely used indices of disease activity
and prognosis [31], and may be useful ancillary indications for
lung transplantation among IPF patients [32].
Although IPF is not widely considered to be an immunologic
disorder, recent studies of patient-derived clinical specimens reveal
the presence of abnormal adaptive immune responses among
Figure 2. Associations of DRB1*1501 and lung function. A.) Forced vital capacities, as percentages of predicted normal values
(FVC%predicted), did not show a consistent association with the presence or absence of DRB1*1501 among the IPF subjects. Aggregate mean values
are denoted by horizontal bars linked by dashed lines. B.) Diffusing capacities, as percentages of predicted normal values (DLCO%predicted), were
decreased among those IPF subjects with DRB1*1501 vs. those patients who did not have this allele, at each participating center. These differences
were significant in comparisons of the cumulative (aggregate) IPF populations, despite considerable overall differences of DLCO%predicted values
(e.g., ‘‘noise’’) between the various participating medical centers (see also Table 1).
doi:10.1371/journal.pone.0014715.g002
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those afflicted by this disease. The majority of IPF patients have
IgG autoantibodies against various autoantigens that are typically
distinct from those described in classical autoimmune syndromes
(e.g., SLE, scleroderma, etc.) [5–8,9,14], and the presence of
particular autoantibody responses in individual IPF patients have
been associated with clinical manifestations of their lung disease
[4,5,9]. In addition, T-cells among IPF patients show increased
extents of prior activation, enhanced production of various
inflammatory and/or pro-fibrotic mediators (e.g., TGF-b1), and
impaired regulatory (Treg) function [10–14,17]. Moreover, first-
degree relatives of patients with familial IPF show intrapulmonary
infiltrations of activated CD4 T-cells many years prior to the
development of clinically-evident lung abnormalities [15]. Acti-
vated, pro-inflammatory dendritic cells with augmented ability to
present antigens to T-cells also accumulate in the pulmonary
parenchyma of IPF patients [18]. CD4 T-cell oligoclonal
proliferation is extensive in the lungs and periphery of IPF
patients, a highly specific finding of repetitive lymphocyte
stimulation by a restricted set of conventional peptide antigens
[13,14]. Abnormal proportions of phenotypically and functionally
distinct CD4+CD28null T-cells, the daughter progeny of repetitive
antigen-driven lymphocyte proliferations, and a frequent and
specific finding of chronic immunologic diseases [47,48], are also
present in the circulation (and lungs) of IPF patients singularly
destined for poor outcomes [16]. Moreover, intrapulmonary
peptide antigen(s) isolated from diseased IPF lungs uniquely drive
proliferations of autologous CD4 T-cells [14].
Considerable efforts have been directed towards discovery of the
genetic determinants for IPF [34,35]. The present data show that
the HLA Class II complex, a unique chromosomal region with
extreme polymorphism, unusually strong, nonrandom LD, and a
high density of diverse immunoregulatory genes [21,38,39],
include one or more loci involved in IPF pathogenesis. These
findings justify further, specific characterizations of targeted HLA
region genes and polymorphisms among IPF cohorts, and
correlative clinical and immunologic functional studies, in order
to ultimately discern the processes that contribute to development
and/or progression of this devastating, intractable disease.
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diagnoses of IPF: SD. In conjunction with Dr. Fuhrman, interpreted and
validated chest CT scans of IPF patients: IO. Provided blinded
radiographic validations of IPF chest CT scans: CF. Provided information
critical for study design, assisted with and validated data analyses: KC. In
conjunction with Dr. Nathan, identified Inova subjects, enrolled them,
obtained and processed specimens, and compiled and analyzed relevant
clinical data for a validation cohort from Inova: MAS. In conjunction with
Dr. Rosen, identified Stanford subjects, enrolled them, obtained and
processed specimens, and compiled and analyzed relevant clinical data for
a validation cohort from Stanford: SSJ. Obtained and processed specimens
of the U. Pgh. transplant population, performed HLA analyses of same.
Provided additional specimens for high resolution typing as well as
technical advice: AZ. Identified control subjects, enrolled them, obtained
and processed specimens, performed HLA analyses, and compiled and
analyzed relevant clinical data for the initial discovery control cohort.
Assisted with data interpretations and manuscript writing: PAM. Identified
transplant recipient subjects, enrolled them, obtained and processed
specimens, and compiled and analyzed relevant clinical data for the initial
IPF discovery cohort. Facilitated or procured specimen acquisitions from
same: JMP. Analyzed data, assisted with study design and identifications of
collaborators and validation cohorts. Assisted with data analyses. Procured
additional data: VGV. Identified ambulatory IPF subjects, recruited them
for these studies, obtained and processed specimens, and compiled and
analyzed relevant clinical data for this validation cohort: KFG NK.
Provided technical assistance and advice. Helped with DNA isolation and
analyses: YZ. Identified normal volunteer subjects, enrolled them, obtained
and processed specimens, and compiled and analyzed relevant clinical data
for a validation control cohort: FCS. Conceived and designed experiments,
coordinated specimen acquistion, processing and analyses, collated clinical
information provided by colleagues, analyzed the data in conjunction with
co-authors, provided financial support of the studies, and wrote the paper:
SRD.
Table 4. Published studies of HLA allele frequencies in IPF.
Loci #Alleles tested
Molecular
diagnoses IPF (n) Abnormal in IPF? year ref
? ? No 20* Yes HLA12 1976 40
-A, -B 24 No 32 no 1977 41
-A, -B 35 No 33 no 1978 42
-A, -B, -C 36 No 50 Yes: B8 1978 43
-A, -B, -C,
-Dw
32
4
No 38* Yes: B15 and Dw6 1979 44
-A, -B, -C, -DR 65 (total in all loci) No 20 Yes: DR2 1983 45
-A, -B, -DR, -DQ 45 multiple Yes 75 Yes, multiple Class I and Class II alleles and
haplotypes (but not DRB1*15)
2005 46
*included patients with other autoimmune syndromes. Approximately fifty (50) HLA-A, 85 HLA-B, 45 HLA-C, 44 HLA-DR, and 16 HLA-DQ distinct polymorphisms (alleles
and suballeles) are currently known to be expressed in Caucasian populations [29].
doi:10.1371/journal.pone.0014715.t004
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